Morning Notes : BARb BB, CRBN NA, EXMb BB, QFG BB, ONWD BB

: BARb BB, CRBN NA, EXMb BB, QFG BB, ONWD BB

Benelux Morning Notes

Belgian telecoms: Orange Belgium's new B2B offensive. BE Semiconductor Industries: Investor Day highlights. Proximus: Sale of Be-Mobile, asset disposals upped from ‘>€500m' to ‘up to €600m'. UCB: To invest in a new US manufacturing site

Galapagos Updated NHL phase 1/2 GLPG5101 data at EHA shows decentralis...

Galapagos will present new data from the ongoing Phase 1/2 (ATALANTA-1) study of GLPG5101 (CD19 CAR-T) at the European Hematology Association (EHA) Congress, being held 12-15 June. The results demonstrate POC for a 7 day vein-vein de-centralised CAR-T manufacturing process. Combined with the previously reported safety differentiation, we believe this could support strategic discussions as the company is exploring such options for its cell therapy business. We reiterate our Buy rating and € 37 TP...

Morning Notes : AGFB BB, BPOST BB, GLPG NA, PROX BB, UCB BB, MAAT FP

: AGFB BB, BPOST BB, GLPG NA, PROX BB, UCB BB, MAAT FP

Dollar Weakness The impact on our Benelux Coverage

In general, a weaker USD has a negative impact on Benelux stocks, particularly for companies with significant exports to the US. In this note we selected a list of companies with high US export exposure and we examine the potential impact on FY25 earninings. On top of the weak dollar, rising trade tensions or the introduction of tariffs further harm Benelux exporters. As the dollar depreciates against the euro, European goods become costlier for American consumers. At the same time, revenues ear...

UCB FIRST LOOK: Expansion of US biologics manufacturing capacity

UCB has announced plans to build a new state-of-the-art biologics manufacturing facility in the US, which today accounts for 55% of its revenues. The investment, estimated at $ 2bn over 6–7 years, is expected to generate a $ 5bn economic impact, including 300 permanent and > 500 construction jobs. This move aligns UCB with other major pharma players expanding US operations and may help mitigate risks from potential US import tariffs on pharmaceuticals. Additionally, UCB will strengthen its partn...

Morning Notes : BESI NA, EVS BB, UCB BB, AUTL US

: BESI NA, EVS BB, UCB BB, AUTL US

UCB FIRS LOOK: Add'l Phase 3 data support dapirolizumab's potential in...

UCB and Biogen presented additional Phase 3 data showing that dapirolizumab pegol (DZP, anti-CD40L) significantly improves fatigue and disease activity in patients with moderate-to-severe systemic lupus erythematosus (SLE). Beyond the positive topline readout in Nov '24, DZP showed superior results over standard care in multiple fatigue and disease remission measures. Accumulate/€214 TP confirmed.

UCB 3-year PsA and axSpA data at EULAR 2025 confirm Bimzelx' efficacy

At EULAR 2025, UCB presented three-year data for Bimzelx, demonstrating sustained efficacy and inflammation control in psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA). In PsA, both biologic-naïve (53.2%) and TNFa-refractory patients (55.2%) maintained strong ACR50 responses and showed high rates of joint and skin symptom resolution. In axSpA, patients with both radiographic and non-radiographic forms sustained ASAS40 responses and low disease activity. These results highlight Bimze...

Morning Notes : ARGX BB, CPINVb BB, UCB BB, BTLS BB

: ARGX BB, CPINVb BB, UCB BB, BTLS BB

UCB - “Bim’ Me Up Scotty” – INITIATION (BUY, TP EUR215, 54pgs)

We initiate with a BUY due to our proprietary Contribution Analysis showing that the UCB EBITDA margin should explode by ~1500bps to ~45% by 2030. This leaves us 23% above consensus EBITDA. Interestingly, Cimzia is the biggest driver of our 5% above cons. 2030 sales as a result of our analysis showing that ~80% of TRx’s are women & this cohort is stable. We show that Bimzelx pricing could fall as much as 30% by 2030 due to rebates & mix but we are still in-line with consensus. There are still ma...

Benelux Local Champions Feedback document

Below our feedback notes written at the occasion of our annual Benelux Local Champions Conference that took place on 27 May 2025 at our historic building at Grand Place Brussels. This event offered the possibility to have one-on-one meetings and/or small group meetings with the following Benelux companies and their top management & IR: ACKERMANS & VAN HAAREN | AHOLD DELHAIZE | AKZONOBEL | ARCADIS | AZELIS | CORBION | GBL | LOTUS BAKERIES | MELEXIS | PROXIMUS | SOFINA | UMICORE

Benelux Morning Notes

Aedifica and Cofinimmo: Agreement reached to create Europe's leading Healthcare REIT. bpost: CMD press release; #Reshape 2029. D'Ieteren: Belgian new car registrations down 11.7% in May, VW down 13.5% Fugro: Meeting with CEO & IR; 2Q25 also has its challenges. UCB: Peer Moonlake held takeover talks with US Merck, FT reports

Galapagos NV: 1 director

A director at Galapagos NV bought 62,273 shares at 28.810USD and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...

Basic-Fit/Strong 1Q25 and momentum continues/BUY

We keep our BUY rating and €30.0 target price. However, we add BFIT back to the ING Benelux Favourites list after it reported a strong 1Q25 trading update, being resilient vs tariff wars and, more importantly, tackled the refinancing of the CB with the new funding obtained while providing comfort on the cash component. The €35m investment in 24/7 gyms in France is well explained and bearing fruits (supported by extra membership ingrowth) while offering upside in earnings if and when the 24/7 mod...

ODDO BHF SECURITIES Small & MIDCAP MORNING NEWS – 05/26/2025